Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts

por Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-Tang, Fu, Beverly D, Hsu, Frank PK, Schönthal, Axel H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil EJC, Stathopoulos, Apostolos
Publicado 2018